The NCCN ORP fosters innovation and knowledge discovery that improve the lives of patients with cancer.
Guiding Principles:
NCCN and Taiho Request for Proposals (RFP) Opportunity: Phase I/II Clinical Trials of Tipiracil/Trifluridine (TAS-102) and/or Futibatinib (TAS-120) for Gastrointestinal Cancers – Submit proposals by Tuesday, November 12, 2024. Open to NCCN Member Institutions only.
NCCN and Taiho Request for Proposals (RFP) Grant Opportunity: Phase I/II Clinical Trials of Zipalertinib (CLN 081/TAS 6417) for Non-Small Cell Lung Cancers with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Uncommon/Compound Mutations – Submit Proposals by Monday, January 6, 2025. Open to NCCN Member Institutions only.
View the NCCN ORP Press Releases
View the NCCN ORP Scientific Publications
View the NCCN ORP Disclosure Policy